Abi	abiraterone
ADT	androgen deprivation therapy
AE	adverse event
Apa	apalutamide
ARPI	androgen receptor pathway inhibitor
CI	confidence interval
Dar	darolutamide
Doc	docetaxel
EMA	European Medicines Agency
Enz	enzalutamide
FDA	Food and Drug Administration
FN	febrile neutropenia
HR	hazard ratio
mHSPC	metastatic hormone-sensitive prostate cancer
NCI-CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
NMA	network meta-analysis
OS	overall survival
PFS	progression-free survival
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT	randomized controlled trial
ROB2	Risk-of-Bias version 2 Tool
RR	risk ratio
SOC	standard of care